Nagi Bioscience
We are a Swiss high-tech company developing and offering cutting-edge biological testing solutions that enable scientists to generate insights they need to fuel life-changing discoveries in a faster, more efficient, and ethical way. Our technologies are designed to integrate seamlessly into existing lab environments, enhancing efficiency, accuracy, and reproducibility.
Advanced Human BBB‐on‐a‐Chip: A New Platform for Alzheimer’s Disease Studies
Erythrocyte-derived extracellular vesicles transcytose across the blood-brain barrier to induce Parkinson’s disease-like neurodegeneration
Synaptic vesicle characterization of iPSC-derived dopaminergic neurons provides insight into distinct secretory vesicle pools
AIM Biotech
AIM Biotech is a leading bioengineering company, offering scalable, cost-effective 3D cell culture platforms, drug screening services, and customized assay development. By combining model realism and platform simplicity, AIM’s plug-and-play technologies empower drug developers to mimic human biology with precision, delivering clinically-relevant data.
Axol BioScience
Axol Bioscience are leaders in human iPSC products and services for CNS, PNS and cardiac research. Under ISO9001, we manufacture functional hiPSC-derived cells with multi-platform utility for MPS technology, alongside a “one-stop shop” of iPSC lines, services and custom assays.
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.
Ncardia
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC).